l carnitine carcinogen L-Carnitine | Linus Pauling Institute Systemic primary carnitine deficiency -

RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)

persons with blood uric acid levels between 7 and 8.9 mg/dL have a 0.53% change of developing the disease, which rises to 4.5% at levels over 9 mg/dL

This suggests that all forms of vitamin B12 methylcobalamin, aquacobalamin, and hydroxocobalamin interact with these biological agents by breaking Co-C or Co-O bonds, except for cyanocobalamin

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal